ZBIOHealthcare · BiotechnologyThe 8 Wall Street analysts covering Zenas BioPharma, Inc. hold a median 12-month price target of $47 — +63.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Zenas BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (71): The shares have been drifting up relative to others.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +63.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $44 |
| 30 Sept 2026 | Citigroup | Maintains | Buy | — |
| 30 Sept 2026 | Citigroup | Maintains | Buy | $41 → $48 |
| 30 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $44 |
| 30 Sept 2026 | Wedbush | Reiterates | Outperform | $45 |
| 30 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 14 Aug 2026 | Guggenheim | Reiterates | Buy | — |
| 14 Aug 2026 | Guggenheim | Reiterates | Buy | $55 |
| 14 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $22 → $32 |
| 14 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Aug 2026 | Wedbush | Reiterates | Outperform | $45 |
| 14 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 15 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $44 |
| 15 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $21 → $22 |
| 17 Mar 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 17 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZBIO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Zenas BioPharma, Inc. returned −5.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 1% of US stocks
Cheaper than 12% of US stocks
Cheaper than 82% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 7% of US stocks
Higher than 12% of US stocks
Higher than 62% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zenas BioPharma, Inc. has a market value of $1.9B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $1.0M.
Net income over the same four quarters: −$484.4M, a −48438.4% net margin.
Diluted earnings per share, trailing twelve months: $−8.99.
Free cash flow in the twelve months to 30 June 2026: −$291.0M.
Trailing P/E: 1.6×; forward P/E: −6.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.03%, paying out 0% of earnings.
Zenas BioPharma, Inc. employs 167 people — $6K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zenas BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zenas BioPharma outlined development plans for obexelimab in systemic lupus erythematosus and for investigational oral IL-17AA/AF inhibitor ZB021 at an R&D event. Clinical data are expected later in the quarter.
Why it matters — The update gives ZBIO watchers information on the company’s plans for two programs and the timing of anticipated clinical data.
Seeking Alpha published a transcript of a Zenas BioPharma R&D event focused on obexelimab in SLE and ZB021 development.
Why it matters — The transcript provides ZBIO watchers with an account of the company’s discussion of these two development programs.
Zacks Investment Research reports that analysts’ mean price target for Zenas BioPharma implies a 77.6% upside. The excerpt cautions that this metric has not proven reasonably effective, while noting that agreement on raising earnings estimates may indicate upside.
Why it matters — ZBIO watchers may note the analysts’ price-target estimate alongside the stated caveat about its reliability and the reported earnings-estimate agreement.
Zenas BioPharma said its Compensation Committee granted 74,900 restricted stock units to newly hired employees on October 15, 2026. The awards were made as employment inducements under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The grant reports equity compensation awarded to new employees and is a corporate update for ZBIO watchers.
Zenas BioPharma announced it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), scheduled for October 21–23, 2026, in Toronto. Topics include orelabrutinib data in relapsing-remitting multiple sclerosis, progressive MS trial designs, and other MS portfolio data.
Why it matters — The presentations will share updates on Zenas’s multiple sclerosis research and clinical trial plans with meeting attendees.
The 8 Wall Street analysts covering Zenas BioPharma, Inc. have a median 12-month price target of $47, with estimates ranging from $32 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Zenas BioPharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zenas BioPharma, Inc. 20 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Zenas BioPharma, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (71 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +63.4% from the last close, and Ticker Nerd's factor model ranks Zenas BioPharma, Inc. 20 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zenas BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $59 over the next 12 months.
Zenas BioPharma, Inc. returned -5.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases.
The most recent item we track (MarketBeat, 30 Oct 2026): "Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears". Zenas BioPharma outlined development plans for obexelimab in systemic lupus erythematosus and for investigational oral IL-17AA/AF inhibitor ZB021 at an R&D event. Clinical data are expected later in the quarter.
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company’s lead program is obexelimab, a bifunctional monoclonal antibody being studied across multiple immune-mediated conditions, including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Zenas BioPharma also advances a broader pipeline of antibody-based and targeted therapies aimed at modulating immune pathways involved in chronic autoimmune disorders. Based in Waltham, Massachusetts, the company operates as a research-driven drug developer with current activities centered on clinical development, regulatory progress, and building a portfolio of therapies for patients with significant unmet medical needs.
CEO Mr. Leon Oliver Moulder Jr., M.B.A. · 167 employees · United States · https://zenasbio.com
